Atrasentan销售预测与市场规模分析（2034 年）

Atrasentan成长的关键驱动因素

1. 扩大市场占有率并增加新患者数量

• Atrasentan是一种选择性内皮素 A (ETA) 受体拮抗剂，已成为 IgA肾臟病(IgAN) 的一种有前景的疾病修正治疗，而 IgA 肾病是一种核准治疗选择有限的疾病。
• 肾臟科医师的认识不断提高，以及强有力的后期临床试验数据有望促进更早地采用和新患者开始治疗，尤其是在持续蛋白尿的高风险 IgAN 患者中。
• 随着治疗模式从支持性治疗和类固醇转向以机制为基础的标靶治疗，预计商业性发展势头也将增强。

2. 主要适应症的扩展

• IgA肾臟病（主要目标）：专为IgA肾病变进展高风险患者研发。显着降低蛋白尿和肾臟保护征兆。
• 慢性肾臟病(CKD) 亚型：鑑于内皮素讯号在肾臟疾病进展中的核心作用，可以对其在更广泛的蛋白尿 CKD 患者群体中的潜在用途进行长期探索。
• 联合治疗的潜力：Atrasentan有潜力与 RAAS 抑制剂和 SGLT2 抑制剂等标准疗法联合使用，从而加强其在综合肾臟疾病管理中的作用。
• 产品线拓展机会：IgAN 的成功可能会推动产品生命週期拓展到其他罕见和进行性肾丝球疾病。

3. 地理扩张

• 美国和欧洲作为核心市场：初步的商业化活动预计将集中在拥有成熟的肾臟病网络和强大的罕见疾病报销框架的地区。
• 亚太地区的成长潜力：中国和日本等国家 IgAN 的高发病率使亚太地区成为一个重要的长期成长地区，但需获得监管部门的核准。
• 全球发展策略：提高人们对 IgAN 是进行性且可治疗的疾病（而不是良性疾病）的认识，将有助于更广泛地在区域内推广应用。

4. 新适应症的核准

• IgAN 的监管申报：在 3 期临床试验取得积极结果后，计划向 IgAN 提交监管申报，这标誌着在满足高度未满足需求的核准方面迈出了重要一步。
• 核准的可能性：利用替代终点（例如蛋白尿减少）可能有助于加速核准，但需后续确认数据。
• 加强产品组合：Atrasentan的核准显着加强了赞助商的肾臟产品组合，并将收入多元化至罕见肾臟疾病领域。

5. IgA肾病变患者数量呈现显着成长趋势

• 未满足的医疗需求很高：儘管采取了最佳的支持性治疗，但许多 IgAN 患者仍会发展为末期肾病。
• 令人信服的疗效征兆：持续且具有临床意义的蛋白尿减少有望推动肾臟科医师大力开立处方。
• 治疗模式的改变：随着人们对 IgAN早期疗育的接受度不断提高，预计长期来看，患者数量将持续成长。

6. 竞争差异化与市场趋势

• 标靶 ETA 受体阻断：Atrasentan具有特异性的作用机制，可减少蛋白尿，同时避免选择性较低的药物所引起的广泛的内皮素相关副作用。
• 口服疗法的便利性：与注射剂或更复杂的治疗方法相比，每日一次口服给药有助于提高患者的依从性。
• 与精准肾臟病学趋势相符：鑑于人们越来越关注基于生物标记的风险分层和早期疾病干预，Atrasentan处于有利地位。
• 真实世界数据 (RWE) 的重要性日益凸显：核准后，真实世界数据对于确保支付方的信心、检验长期安全性以及推进治疗指南至关重要。

Atrasentan的最新趋势

2025年4月，诺华公司宣布，美国食品药物管理局（FDA）加速批准了肾臟病（Atrasentan）上市，这是一种原发性且选择性的内皮素A（ETA）受体拮抗剂，用于降低原发性IgA肾病（IgAN）成人患者的蛋白尿，蛋白尿通常定义为快速/肌酸酐 5.55965/202550005/225925055 -g + /核准的风险。 VANRAFIA为每日一次的非类固醇口服药物，可与包括肾素-血管收缩素系统（RAS）抑制剂（可合併或不合併SGLT2抑制剂）在内的支持性治疗合併使用。

《Atrasentan销售预测及市场规模分析（2034）》报告已通过核准分析了阿曲生坦在七大主要市场（美国、欧盟四国（德国、法国、义大利和西班牙）、英国、法国、义大利和西班牙）的已核准适应症，以及潜在适应症，例如修格兰氏症候群全身性红斑性狼疮、新生儿同种免疫性血小板减少症、干燥症和系统性红斑狼疮。本报告详细分析了Atrasentan在七大主要市场（美国、欧盟四国（德国、法国、义大利和西班牙）、英国和日本）的现有用途、已通过核准，Atrasentan週期为2020年至2034年。此外，报告也对Atrasentan已通过核准和潜在适应症进行了详细描述。这份Atrasentan市场报告深入分析了Atrasentan的销售预测、作用机制、剂量和给药途径，以及研发和其他开发活动，包括监管里程碑。此外，该报告还对市场进行了详细分析，包括Atrasentan过去和当前的市场表现、未来市场评估（包括对七个主要国家已通过核准和潜在适应症的Atrasentan市场预测分析）、SWOT分析、分析师观点、市场竞争对手的全面概述，以及针对每种适应症的其他新兴治疗方法的概述。报告中还对Atrasentan的销售预测和市场驱动因素进行了分析。

Atrasentan药物概述

Atrasentan（VANRAFIA）是由诺华公司研发的一种口服选择性内皮素A受体（ETAR或ETA）拮抗剂，用于治疗免疫球蛋白A肾臟病（IgAN），这是进行性肾臟疾病。它具有高度选择性（ETA的Ki值为0.034 nM，ETB的Ki值为63.3 nM），可抑制内皮素-1与肾臟细胞上ETA受体的结合。这可以减轻肾丝球高血压、远端小动脉血管收缩、发炎、纤维化和蛋白尿，同时保护肾功能。该药于2025年获得美国食品药物管理局（FDA）核准，用于治疗有快速进展风险的IgAN成人患者。每日一次（0.75 mg）给药，需合併标准症状治疗，包括肾素-血管收缩素系统阻断剂。第三期临床研究证实，阿曲生坦可显着降低蛋白尿。本报告提供有关Atrasentan在多种适应症中的销售情况、成长抑制因素和驱动因素、使用情况和核准情况的资讯。

Atrasentan目前处于 II 期临床开发阶段，用于治疗 IgA肾臟病患者（NCT04573920）。

Atrasentan市场报告的研究范围

本报告深入分析了以下内容：

• 对Atrasentan进行全面的产品概述，包括其作用机制（MoA）、产品说明、剂量和给药方法，以及针对核准适应症（如重症肌无力）和潜在适应症（如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮）的研究和开发活动。
• 这份Atrasentan市场报告提供了有关监管里程碑和其他发展活动的详细资讯。
• 该报告还重点介绍了Atrasentan在美国、欧洲和日本已通过核准和潜在适应症的成本估算和区域差异、已报告和估计的销售额以及研发活动。
• 这份Atrasentan市场报告还涵盖了专利资讯、学名药上市及其对降低成本的影响。
• 这份Atrasentan市场报告包含了Atrasentan在已通过核准和潜在适应症范围内的当前和预测销售情况，直至 2034 年。
• 此外，也全面介绍了每种适应症中新兴的后期治疗方法。
• 这份Atrasentan市场报告还包括对Atrasentan在已通过核准和潜在适应症方面的 SWOT 分析和分析师观点。

调查方法：

本Atrasentan市场报告主要基于从内部资料库、一手和二手研究以及DelveInsight行业专家团队的内部分析中获得的数据和资讯。二级资讯来源和非印刷管道，例如搜寻引擎、新闻网站、世界各地的监管机构网站、行业期刊、白皮书、杂誌、书籍、行业协会、贸易入口网站以及对现有资料库的存取。

DelveInsight的Atrasentan分析观点

• 对Atrasentan市场的详细评估

这份Atrasentan销售市场预测报告对七个主要市场——美国、欧盟四国（德国、法国、义大利、西班牙）、英国和日本——进行了核准的市场评估，涵盖了已获批准的适应症（如重症血小板减少性疾病、新生儿同种免疫性血小板减少症、修格兰氏症候群和全身性红斑性狼疮）。报告的这一部分提供了阿曲生Atrasentan截至2034年的当前销售数据和预测销售数据。

• Atrasentan的临床评价

这份Atrasentan市场报告提供了有关Atrasentan已通过核准和潜在适应症的临床试验信息，包括研究干预措施、研究条件、实验状况以及开始和完成日期。

Atrasentan的竞争格局

本报告深入分析了该领域的竞争对手和市售产品，并概述了新兴产品及其预计上市日期，这些产品将成为市场上的主要竞争者。

Atrasentan市场潜力及收入预测

• Atrasentan及其主要适应症：预计市场规模
• Atrasentan的预期销售潜力（销售尖峰时段预测）
• Atrasentan定价策略和报销情况

Atrasentan竞争讯息

• 在研竞争药物数量（研发管线分析）
• Atrasentan与现有疗法相比的市场定位
• Atrasentan坦相对于竞争对手的优势和劣势

Atrasentan监理与商业里程碑

• Atrasentan的关键监管核准和预计上市时间
• 商业合作、授权协议和併购活动

Atrasentan的临床鑑别诊断

• 与现有药物相比，Atrasentan具有更优的疗效和安全性
• Atrasentan的独特优势

Atrasentan市场报告要点

• 未来几年，随着阿曲生坦的广泛应用、处方笺的增加以及在多种免疫学适应症中的更广泛应用，预计Atrasentan市场将发生变化，这将推动市场规模的成长。
• Atrasentan相关企业正在开发以治疗和改善疾病状态的新方法为重点的治疗方法，以评估可能影响Atrasentan优势的挑战和机会。
• 其他用于治疗重症肌无力的新兴产品，以及胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮等潜在适应症，预计将对Atrasentan构成激烈的市场竞争，而近期推出的后期治疗方法预计也将对市场产生重大影响。
• 它提供了Atrasentan在已通过核准和潜在适应症中的最新进展情况，并详细说明了监管里程碑和研发活动。
• 分析Atrasentan的成本、定价趋势和市场定位，以支持免疫学领域的策略决策。
• 我们对Atrasentan销售预测数据（截至 2034 年）的详细分析将帮助您决策流程，透过确定Atrasentan在已通过核准和潜在适应症中的整体情况。

目录

第一章 报告概述

第二章Atrasentan概述：核准的适应症，例如重症肌无力；以及潜在的适应症，例如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮。

• 产品详情
• Atrasentan的临床开发
  • Atrasentan的临床研究
  • Atrasentan临床试验资讯
  • 安全性和有效性
• 其他发展活动
• 产品简介

第三章Atrasentan（上市治疗药物）的竞争格局

第四章 竞争格局（后期Atrasentan疗法）

第五章Atrasentan市场评估

• Atrasentan在已通过核准和潜在适应症的市场展望
• 对七个主要国家的分析
  • Atrasentan在七个主要国家已已通过核准和潜在适应症的市场规模
• 各国市场
  • Atrasentan（已通过核准和潜在适应症）在美国的市场规模
  • Atrasentan在德国的市场规模（已通过核准和潜在适应症）
  • 英国Atrasentan市场规模（已通过核准和潜在适应症）

第六章Atrasentan的SWOT分析

第七章 分析师观点

第八章附录

第九章 DelveInsight 服务

第十章 免责声明

第十一章 关于 DelveInsight

第十二章 报告购买选项

Key Factors Driving Atrasentan Growth

1. Market Share Gains and New Patient Starts

• Atrasentan, a selective endothelin A (ETA) receptor antagonist, is emerging as a high-potential disease-modifying therapy in IgA nephropathy (IgAN), a condition with limited approved treatment options.
• Growing nephrologist awareness and strong late-stage clinical data are expected to drive early adoption and new patient starts, particularly among high-risk IgAN patients with persistent proteinuria.
• Commercial momentum is anticipated as treatment paradigms shift from supportive care and steroids toward targeted, mechanism-based therapies.

2. Expansion Across Key Indications

• IgA Nephropathy (Primary Focus): Atrasentan is being developed for patients with IgAN at high risk of progression, supported by robust reductions in proteinuria and favorable kidney protection signals.
• Chronic Kidney Disease (CKD) Subsets: Given the central role of endothelin signaling in kidney disease progression, there is longer-term potential to explore use in broader proteinuric CKD populations.
• Combination Therapy Potential: Atrasentan may be positioned alongside standard-of-care therapies such as RAAS inhibitors and SGLT2 inhibitors, strengthening its role in comprehensive renal disease management.
• Pipeline Expansion Opportunities: Success in IgAN could enable lifecycle expansion into other rare or progressive glomerular diseases.

3. Geographic Expansion

• U.S. and Europe as Core Markets: Initial commercialization efforts are expected to focus on regions with established nephrology networks and strong rare-disease reimbursement frameworks.
• Asia-Pacific Growth Potential: High IgAN prevalence in countries such as China and Japan positions Asia-Pacific as a significant long-term growth region, pending regulatory approvals.
• Global Development Strategy: Broader geographic expansion will be supported by increasing recognition of IgAN as a progressive, treatable disease rather than a benign condition.

4. New Indication Approvals

• Regulatory Filings in IgAN: Positive Phase III outcomes support planned regulatory submissions for IgAN, representing a major step toward approval in a high-unmet-need indication.
• Potential for Accelerated or Conditional Pathways: Use of surrogate endpoints such as proteinuria reduction may facilitate earlier approvals, with confirmatory outcomes data to follow.
• Portfolio Strengthening: Approval of atrasentan would significantly enhance its sponsor's renal portfolio and diversify revenue into rare kidney diseases.

5. Strong IgAN Volume Momentum

• High Unmet Clinical Need: Many IgAN patients continue to progress to end-stage kidney disease despite optimized supportive care.
• Compelling Efficacy Signals: Consistent and clinically meaningful reductions in proteinuria are expected to drive strong prescribing momentum among nephrologists.
• Shifting Treatment Paradigms: Increasing acceptance of early intervention in IgAN is expected to support sustained patient volumes over time.

6. Competitive Differentiation and Market Trends

• Targeted ETA Receptor Blockade: Atrasentan offers a focused mechanism that reduces proteinuria while avoiding broader endothelin-related side effects seen with less selective agents.
• Oral Therapy Convenience: Once-daily oral dosing supports patient adherence compared with injectable or more complex regimens.
• Alignment with Precision Nephrology Trends: Growing emphasis on biomarker-driven risk stratification and early disease intervention favors atrasentan's positioning.
• Increasing Role of Real-World Evidence (RWE): Post-approval RWE will be important for payer confidence, long-term safety validation, and expansion of treatment guidelines.

Atrasentan Recent Developments

In April 2025, Novartis announced the US Food and Drug Administration (FDA) granted accelerated approval for VANRAFIA (Atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) >=1.5 g/g. VANRAFIA is a once-daily, non-steroidal, oral treatment that can be added onto supportive care, including a renin-angiotensin system (RAS) inhibitor with or without a sodium-glucose co-transporter-2 (SGLT2) inhibitor.

"Atrasentan Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Atrasentan for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the 7MM. A detailed picture of Atrasentan's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Atrasentan for approved and potential indications. The Atrasentan market report provides insights about Atrasentan's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Atrasentan performance, future market assessments inclusive of the Atrasentan market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Atrasentan sales forecasts, along with factors driving its market.

Atrasentan Drug Summary

Atrasentan (brand name VANRAFIA) is an oral, selective endothelin A receptor (ETAR or ETA) antagonist developed by Novartis for treating immunoglobulin A nephropathy (IgAN), a progressive kidney disease characterized by proteinuria. With high selectivity (Ki = 0.034 nM for ETA versus 63.3 nM for ETB), it blocks endothelin-1 binding to ETA receptors on renal cells, reducing glomerular hypertension, efferent arteriolar vasoconstriction, inflammation, fibrosis, and proteinuria while preserving renal function. FDA-approved in 2025 for adults with IgAN at risk of rapid progression, it is dosed once daily (0.75 mg) alongside standard supportive care like renin-angiotensin system blockade, showing clinically meaningful proteinuria reductions in Phase III trials. The report provides Atrasentan's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Atrasentan is in the Phase II stage of clinical development for the treatment of patients with IgA Nephropathy (NCT04573920).

Scope of the Atrasentan Market Report

The report provides insights into:

• A comprehensive product overview including the Atrasentan MoA, description, dosage and administration, research and development activities in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus.
• Elaborated details on Atrasentan regulatory milestones and other development activities have been provided in Atrasentan market report.
• The report also highlights Atrasentan's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Atrasentan market report also covers the patents information, generic entry and impact on cost cut.
• The Atrasentan market report contains current and forecasted Atrasentan sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Atrasentan market report also features the SWOT analysis with analyst views for Atrasentan in approved and potential indications.

Methodology:

The Atrasentan market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Atrasentan Analytical Perspective by DelveInsight

• In-depth Atrasentan Market Assessment

This Atrasentan sales market forecast report provides a detailed market assessment of Atrasentan for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Atrasentan sales data uptil 2034.

• Atrasentan Clinical Assessment

The Atrasentan market report provides the clinical trials information of Atrasentan for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Atrasentan Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Atrasentan Market Potential & Revenue Forecast

• Projected market size for the Atrasentan and its key indications
• Estimated Atrasentan sales potential (Atrasentan peak sales forecasts)
• Atrasentan Pricing strategies and reimbursement landscape

Atrasentan Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Atrasentan Market positioning compared to existing treatments
• Atrasentan Strengths & weaknesses relative to competitors

Atrasentan Regulatory & Commercial Milestones

• Atrasentan Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Atrasentan Clinical Differentiation

• Atrasentan Efficacy & safety advantages over existing drugs
• Atrasentan Unique selling points

Atrasentan Market Report Highlights

• In the coming years, the Atrasentan market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Atrasentan companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Atrasentan's dominance.
• Other emerging products for Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus are expected to give tough market competition to Atrasentan and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Atrasentan in approved and potential indications.
• Analyse Atrasentan cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Atrasentan sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Atrasentan in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Atrasentan? How strong is Atrasentan's clinical and commercial performance?
• What is Atrasentan's clinical trial status in each individual indications such as Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Atrasentan Manufacturers?
• What are the key designations that have been granted to Atrasentan for approved and potential indications? How are they going to impact Atrasentan's penetration in various geographies?
• What is the current and forecasted Atrasentan market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Atrasentan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Atrasentan for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Atrasentan? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Atrasentan Overview in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus

• 2.1. Product Detail
• 2.2. Atrasentan Clinical Development
  • 2.2.1. Atrasentan Clinical studies
  • 2.2.2. Atrasentan Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Atrasentan Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Atrasentan Therapies)

5. Atrasentan Market Assessment

• 5.1. Atrasentan Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Atrasentan Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Atrasentan Market Size in the United States for approved and potential indications
  • 5.3.2. Atrasentan Market Size in Germany for approved and potential indications
  • 5.3.3. Atrasentan Market Size in France for approved and potential indications
  • 5.3.4. Atrasentan Market Size in Italy for approved and potential indications
  • 5.3.5. Atrasentan Market Size in Spain for approved and potential indications
  • 5.3.6. Atrasentan Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Atrasentan Market Size in Japan for approved and potential indications

6. Atrasentan SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Atrasentan, Clinical Trial Description, 2023
• Table 2: Atrasentan, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Atrasentan's pricing and cost Assumptions
• Table 6: Atrasentan's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Atrasentan Market Size in the US, in USD million (2020-2034)
• Table 8: Atrasentan Market Size in Germany, in USD million (2020-2034)
• Table 9: Atrasentan Market Size in France, in USD million (2020-2034)
• Table 10: Atrasentan Market Size in Italy, in USD million (2020-2034)
• Table 11: Atrasentan Market Size in Spain, in USD million (2020-2034)
• Table 12: Atrasentan Market Size in the UK, in USD million (2020-2034)
• Table 13: Atrasentan Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Atrasentan's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Atrasentan Market Size in the United States, USD million (2020-2034)
• Figure 3: Atrasentan Market Size in Germany, USD million (2020-2034)
• Figure 4: Atrasentan Market Size in France, USD million (2020-2034)
• Figure 5: Atrasentan Market Size in Italy, USD million (2020-2034)
• Figure 6: Atrasentan Market Size in Spain, USD million (2020-2034)
• Figure 7: Atrasentan Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Atrasentan Market Size in Japan, USD million (2020-2034)